Editas Cash and Equivalents from 2010 to 2024

EDIT Stock  USD 7.44  0.22  3.05%   
Check Editas Medicine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Editas main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.2 M, Interest Expense of 3 M or Selling General Administrative of 57.9 M, as well as many exotic indicators such as Price To Sales Ratio of 9.36, Dividend Yield of 0.0 or Operating Cycle of 49.97. Editas financial statements analysis is a perfect complement when working with Editas Medicine Valuation or Volatility modules.
  
This module can also supplement Editas Medicine's financial leverage analysis and stock options assessment as well as various Editas Medicine Technical models . Check out the analysis of Editas Medicine Correlation against competitors.
For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.

About Editas Medicine Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Editas Medicine income statement, its balance sheet, and the statement of cash flows. Editas Medicine investors use historical funamental indicators, such as Editas Medicine's Cash and Equivalents, to determine how well the company is positioned to perform in the future. Although Editas Medicine investors may use each financial statement separately, they are all related. The changes in Editas Medicine's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Editas Medicine's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Editas Medicine Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Editas Medicine. Please read more on our technical analysis and fundamental analysis pages.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. Editas Medicine operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 264 people.

Pair Trading with Editas Medicine

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Editas Medicine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Editas Medicine will appreciate offsetting losses from the drop in the long position's value.

Moving together with Editas Stock

  0.73MBRX Moleculin Biotech Upward RallyPairCorr

Moving against Editas Stock

  0.6MRK Merck Company Fiscal Quarter End 31st of March 2024 PairCorr
  0.47DNTH Dianthus Therapeutics Symbol ChangePairCorr
  0.45VBIV VBI Vaccines Financial Report 20th of May 2024 PairCorr
The ability to find closely correlated positions to Editas Medicine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Editas Medicine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Editas Medicine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Editas Medicine to buy it.
The correlation of Editas Medicine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Editas Medicine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Editas Medicine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Editas Medicine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Editas Medicine is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Editas Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Editas Medicine Stock. Highlighted below are key reports to facilitate an investment decision about Editas Medicine Stock:
Check out the analysis of Editas Medicine Correlation against competitors.
For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.
You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.

Complementary Tools for Editas Stock analysis

When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Fundamental Analysis
View fundamental data based on most recent published financial statements
Money Managers
Screen money managers from public funds and ETFs managed around the world
CEOs Directory
Screen CEOs from public companies around the world
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Is Editas Medicine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Editas Medicine. If investors know Editas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Editas Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.02)
Revenue Per Share
1.028
Quarterly Revenue Growth
8.187
Return On Assets
(0.21)
Return On Equity
(0.43)
The market value of Editas Medicine is measured differently than its book value, which is the value of Editas that is recorded on the company's balance sheet. Investors also form their own opinion of Editas Medicine's value that differs from its market value or its book value, called intrinsic value, which is Editas Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Editas Medicine's market value can be influenced by many factors that don't directly affect Editas Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Editas Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Editas Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Editas Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.